Shockwave will purchase outstanding Neovasc shares for $27.25 each, valuing the company at around $100 million, according to a Jan. 17 news release from Shockwave. Neovasc specializes in the treatment of refractory angina.
Neovasc’s board approved the transaction, which is expected to close in the first half of 2023.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
